Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Tandem Diabetes to $50 from $70 and keeps an Overweight rating on the shares. The company’s Q4 results slightly missed and guidance for the year was lowered modestly on sales while he EBITDA outlook requires a steep ramp in the back half of the year, the analyst tells investors in a research note. Piper expects more pressure on the stock today but does "not see a reason to abandon the name now."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TNDM:
- 3 Stocks to Buy Today, 2/24/2023, According to Top Analysts
- Tandem Diabetes price target lowered to $52 from $61 at Cowen
- Tandem Diabetes price target lowered to $40 from $45 at Baird
- Tandem Diabetes price target lowered to $71 from $76 at Barclays
- Tandem Diabetes sees FY23 revenue $885M-$900M, consensus $891.6M